Abstract
Idiotype (Id) vaccination provides an innovative treatment modality against B-cell malignancies. In multiple myeloma patients, however, the antitumoral potential of this immunotherapeutic concept is limited. In an attempt to improve the therapeutic effectiveness of Id vaccination, we added Flt3 ligand (Flt3-L) and interleukin 2 (IL-2) to the protocol. Balb/c mice were inoculated i.p. (d -2) with different doses (1-5 x 10(5)) of HOPC myeloma cells, secreting the IgHOPC Id-protein. Two days later, animals were treated with Flt3-L (10 microg per mouse/d, given i.p) for 10 consecutive days (d 0-9). On d 5 and d 11, myeloma-specific immunoglobulin (Ig(HOPC)) was administered s.c., together with incomplete Freund adjuvans (IFA) followed by the administration of IL-2 (2 x 10.000/d given i.p) for 10 d (d 5-14). Whereas Ig(HOPC), Flt3-L or IL-2, given alone, did not elicit long-term survival, the combination of IL-2 or Flt3-L with Id vaccination achieved a complete tumour rejection in 27% and 41% of mice respectively. However, the most powerful antimyeloma effects were induced by Flt3-L + Id vaccination + IL-2: 81% of the treated animals experienced long-term survival (> 180 d). Both natural killer (NK) cells and CD8+ T cells may be inv...Continue Reading
References
Dec 1, 1971·Proceedings of the National Academy of Sciences of the United States of America·S Sirisinha, H N Eisen
Jun 1, 1972·Proceedings of the National Academy of Sciences of the United States of America·R G LynchH N Eisen
Dec 1, 1995·Nature Medicine·J I MayordomoA B Deleo
Nov 1, 1995·European Journal of Immunology·B BogenG F Lauritzsen
Mar 1, 1994·European Journal of Immunology·V FlamandM Moser
Oct 1, 1996·Proceedings of the National Academy of Sciences of the United States of America·L W KwakS D Weeks
Nov 1, 1996·The Journal of Experimental Medicine·E MaraskovskyH J McKenna
Jun 5, 1997·The New England Journal of Medicine·R Bataille, J L Harousseau
Jun 1, 1997·Nature Medicine·D H LynchJ C Schuh
Aug 4, 1997·The Journal of Experimental Medicine·R JosienM C Cuturi
Nov 14, 1997·Molecular Medicine Today·A Bianchi, M Massaia
Mar 3, 1999·Proceedings of the National Academy of Sciences of the United States of America·K ShimizuJ J Mulé
Mar 12, 1999·Annual Review of Medicine·J M Timmerman, R Levy
Apr 1, 1999·Biotechnology and Bioengineering·E P MeloJ M Cabral
Sep 4, 1999·Cancer Immunology, Immunotherapy : CII·H J McKenna
Sep 30, 1999·Nature Medicine·M BendandiL W Kwak
Dec 3, 1999·British Journal of Haematology·G CullN Russell
Mar 17, 2000·Leukemia·M ZhaoT Naoe
Apr 26, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·J M Timmerman, R Levy
May 3, 2000·British Journal of Haematology·S TitzerH Bohlen
Feb 27, 2001·Blood·A B PawlowskaB R Blazar
Mar 10, 2001·Blood·Y J WenQ Yi
Mar 30, 2001·Bone Marrow Transplantation·M ZeisL Uharek
Citations
Jul 27, 2005·British Journal of Haematology·S J Harrison, G Cook
May 15, 2003·Hematology·Tomas BüchlerRoman Hajek
Feb 21, 2008·Cancer·Justin StebbingHyam Levitsky
Dec 21, 2002·British Journal of Haematology·Jan StritzkeMatthias Zeis
Apr 13, 2021·Frontiers in Oncology·Haichao ZhaoJiefeng He